Skip to search formSkip to main contentSkip to account menu
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
View on PubMed
Angiogenesis in brain tumours
TLDR
Emerging preclinical and clinical data indicate that anti-VEGF therapies are potentially effective in glioblastoma and can transiently normalize tumour vessels, creating a window of opportunity for optimally combining chemotherapeutics and radiation.
View on Nature
An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
View on Elsevier
Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report.
TLDR
An aggressive multimodality therapy can prevent neurologic deterioration and is associated with a prolonged survival in a subset of patients.
View on PubMed
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.
TLDR
It is suggested that class prediction models, based on defined molecular profiles, classify diagnostically challenging malignant gliomas in a manner that better correlates with clinical outcome than does standard pathology.
View on PubMed
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.
TLDR
Genomic analysis of brain metastases provides an opportunity to identify potentially clinically informative alterations not detected in clinically sampled primary tumors, regional lymph nodes, or extracranial metastases, suggesting that sequencing of primary biopsies alone may miss a substantial number of opportunities for targeted therapy.
View on PubMed
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.
TLDR
An international group of experts meeting to review current standards of reporting and to formulate a consensus opinion regarding minimum baseline evaluation and common standards for assessing response to therapy hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow to develop better therapies for patients.
View on PubMed
Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.
TLDR
The results indicate that high-dose methotrexate is associated with modest toxicity and a radiographic response proportion comparable to more toxic regimens.
View on PubMed
Biomarkers of response and resistance to antiangiogenic therapy
TLDR
The current challenges in establishing biomarkers of antiangiogenic therapy are discussed, a number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I–III studies, and all of them need to be validated prospectively.
View on Nature
Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium.
TLDR
Because of the disease rarity, international, multicenter, collaborative efforts are required to better understand the biology and pathogenesis of PVRL as well as to define both diagnostic markers and optimal therapies.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License